The rapid expansion of GLP-1 drug prescriptions is producing a mix of benefits and unintended consequences, according to a report published Thursday by Science | AAAS. The outlet highlights that these medications, originally developed for diabetes, are now being widely used for weight loss, raising questions about long-term effects on patients and healthcare systems.
Science | AAAS notes that the surge in prescribing has outpaced clinical understanding of how these drugs affect diverse populations over extended periods. While the treatments have shown effectiveness in reducing weight, the report points to emerging concerns about muscle loss, gastrointestinal issues, and the psychological impact of dependence on the medication. The journal also flags potential economic ripple effects, including higher costs for insurers and pressure on supply chains for diabetes patients who rely on the same drugs.
The report follows a separate opinion piece in The Washington Post, in which a user of Ozempic describes experiencing public judgment and shaming despite achieving health goals. That commentary, published earlier this week, underscores a growing social tension: patients who use GLP-1s for weight loss often face accusations of taking an "easy way out," even as medical experts debate the appropriateness of long-term use.
